|Day Low/High||179.55 / 182.41|
|52 Wk Low/High||127.67 / 181.60|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BA, CAI, CNHI, FFWM, FSV, NEP, NOW, TGI, TRK, TSU, WPG Downgrades: AAT, BLMN, FBR, GSK, HZO, QDEL, VRTX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2017.
Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday
U.S. stock futures are marginally higher on Wednesday ahead of an announcement from the Federal Reserve on interest rates.
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc.
Wall Street's first glimpse at the second quarter.
The Nasdaq and S&P 500 ended at records for the second day in a row.
S&P 500 and Nasdaq at record highs.
Remarkable data was released from Vertex's triple regiment combination trials.
Vertex Pharmaceuticals, FibroGen and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading trading on July 19.
Cystic fibrosis is an inherited disorder that causes damage to the lungs, digestive system, and other organs of the body.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis (CF) who have one F508del...
Vertex, Boston Public Schools (BPS) and the University of Massachusetts today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride scholarship to pursue an education in...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2017 financial results on Wednesday, July 26, 2017 after the financial markets close.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco, or AIFA) has agreed to reimburse ORKAMBI ® (lumacaftor/ivacaftor), the first...
The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.
You're thinking about your retirement all wrong.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Tuesday, June 13, 2017 at 12:20 p.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced nine presentations of data on ORKAMBI ® (lumacaftor/ivacaftor) and KALYDECO ® (ivacaftor) at the 40 th European Cystic Fibrosis Society...
Shareholders of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today elected Alan M.
Here are Friday's top research calls, including a downgrade for Automatic Data Processing, new coverage of Charter and Coty, and upgrades for Deere and Ulta Beauty.
Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund ORKAMBI ® (lumacaftor/ivacaftor) for all...
The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.